Abstract
Background
Overexpression of periostin (POSTN) is associated with prostate cancer (PCa) aggressiveness.
We investigated the prognostic significance of POSTN expression in tumor biopsy samples
of patients with PCa.
Methods
We scored POSTN expression by immunohistochemistry analysis on 215 PCa biopsy samples
using an anti–POSTN-specific antibody. A total immunoreactive score (T-IRS) was calculated
by adding the POSTN staining scores of stromal and epithelial tumor cells. Prostate-specific
antigen (PSA) progression/recurrence-free survival (PFS), radiographic progression/recurrence-free
survival (rPFS), and overall survival (OS) were the study end points.
Results
A total of 143 patients received therapy with radical attempt, whereas 72 had locally
advanced or metastatic disease and received hormone therapy alone. Median T-IRS was
9 and 12 (range, 0-20), respectively (P = .001). Overall, we found a weak positive correlation of T-IRS with prebiopsy PSA
levels (r = 0.166, P = .016) and Gleason score (r = 0.266, P < .000). T-IRS ≥ 8 independently predicted for shorter PSA-PFS and OS (hazard ratio
[HR] [95% confidence interval (CI)] ≥ 8 versus < 8: 1.50 [1.06-2.14], P = .024 and 1.92 [1.20-3.07], P = .007, respectively). In the subgroup analysis, the association between T-IRS and
patient outcome was retained in patients who received therapy with radical attempt
(HR [95% CI] ≥ 8 vs. < 8: rPFS: 2.06 [1.18-3.58], P = .01; OS: 2.36 [1.24-4.50], P = .009) and in those with low to intermediate Gleason scores (HR [95% CI] ≥ 8 vs. <
8: PSA-PFS: 1.65 [1.06-2.59], P = .028; rPFS: 2.09 [1.14-3.87], P = .018; OS: 2.57 [1.31-5.04], P = .006).
Conclusion
POSTN T-IRS on PCa biopsy samples independently predicted the risk of recurrence,
progression, and death in patients with localized disease and in those with low to
intermediate Gleason scores.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- CA Cancer J Clin. 2016; 66: 7-30
- NCCN clinical practice guidelines: prostate cancer, version 01.2018.(Available at:)
- Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.Eur Urol. 2008; 54: 371-381
- Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.N Engl J Med. 2017; 377: 352-360
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med. 2015; 373: 737-746
- The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.Prostate. 2009; 69: 1398-1403
- Periostin is up-regulated in high grade and high stage prostate cancer.BMC Cancer. 2010; 10: 273
- Periostin: a promising target of therapeutical intervention for prostate cancer.J Transl Med. 2011; 9: 99
- Periostin: a novel prognostic and therapeutic target for genitourinary cancer?.Clin Genitourin Cancer. 2014; 12: 301-311
- Periostin mediates TGF-beta–induced epithelial mesenchymal transition in prostate cancer cells.Cell Physiol Biochem. 2015; 36: 799-809
- Overexpression of periostin in stroma positively associated with aggressive prostate cancer.PLoS One. 2015; 10: e0121502
- Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.BMC Cancer. 2012; 12: 625
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol. 2008; 26: 1148-1159
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247
- Nonparametric estimation from incomplete observations.J Am Stat Assoc. 1958; 53: 457-481
- Regression models and life-tables.J R Stat Soc Ser B. 1972; 34: 187-220
- Interactions between cancer stem cells and their niche govern metastatic colonization.Nature. 2012; 481: 85-89
- Periostin: a bridge between cancer stem cells and their metastatic niche.Cell Stem Cell. 2012; 10: 111-112
- Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update.Virchows Arch. 2011; 459: 465-475
- Targeting the adaptive molecular landscape of castration-resistant prostate cancer.EMBO Mol Med. 2015; 7: 878-894
- Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.Oncotarget. 2015; 6: 23959-23986
- Integrative genomic profiling of human prostate cancer.Cancer Cell. 2010; 18: 11-22
- Biomarkers in prostate cancer—current clinical utility and future perspectives.Crit Rev Oncol Hematol. 2017; 120: 180-193
Article info
Publication history
Published online: July 27, 2018
Accepted:
July 20,
2018
Received in revised form:
July 19,
2018
Received:
April 4,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
